Significant improvement of facial actinic keratoses after blue light photodynamic therapy with oral vitamin D pretreatment: An interventional cohort-controlled trial.

ABSTRACT:

Background

In mouse models of skin cancer, high-dose oral vitamin D3 (VD3; cholecalciferol) combined with photodynamic therapy (PDT) can improve the clearance of squamous precancers (actinic keratoses [AKs]).

Objective

To determine whether oral VD3 can improve the clinical efficacy of a painless PDT regimen in humans with AK.

Methods

The baseline lesion counts and serum 25-hydroxyvitamin D₃ levels were determined. In group 1, 29 patients underwent gentle debridement and 15-minute aminolevulinic acid preincubation with blue light (30 minutes; 20 J/cm²). In group 2, 29 patients took oral VD3 (10,000 IU daily for 5 or 14 days) prior to debridement and PDT. Lesion clearance was assessed at 3 to 6 months.

Results

In group 1, the mean clearance

SUBMITTER: Bullock TA 

PROVIDER: S-EPMC9233022 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature